Biomm SA banner

Biomm SA
BOVESPA:BIOM3

Watchlist Manager
Biomm SA Logo
Biomm SA
BOVESPA:BIOM3
Watchlist
Price: 6.3 BRL 3.11% Market Closed
Market Cap: R$862.1m

Net Margin

-35.5%
Current
Improving
by 23.1%
vs 3-y average of -58.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-35.5%
=
Net Income
R$-49.4m
/
Revenue
R$139m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-35.5%
=
Net Income
R$-49.4m
/
Revenue
R$139m

Peer Comparison

Country Company Market Cap Net
Margin
BR
Biomm SA
BOVESPA:BIOM3
825.7m BRL
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
407.7B USD
Loading...
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
208.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
185.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
125.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
71.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
39.9B EUR
Loading...

Market Distribution

Lower than 92% of companies in Brazil
Percentile
8th
Based on 634 companies
8th percentile
-35.5%
Low
-6 965.9% — 2.1%
Typical Range
2.1% — 15.5%
High
15.5% — 1 493%
Distribution Statistics
Brazil
Min -6 965.9%
30th Percentile 2.1%
Median 8.9%
70th Percentile 15.5%
Max 1 493%

Biomm SA
Glance View

Market Cap
862.1m BRL
Industry
Biotechnology

BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.

BIOM3 Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-35.5%
=
Net Income
R$-49.4m
/
Revenue
R$139m
What is Biomm SA's current Net Margin?

The current Net Margin for Biomm SA is -35.5%, which is above its 3-year median of -58.6%.

How has Net Margin changed over time?

Over the last 3 years, Biomm SA’s Net Margin has increased from -86% to -35.5%. During this period, it reached a low of -99.4% on Sep 30, 2022 and a high of -35.5% on Jun 30, 2025.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett